241 related articles for article (PubMed ID: 20332355)
1. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.
Castle JR; Engle JM; El Youssef J; Massoud RG; Yuen KC; Kagan R; Ward WK
Diabetes Care; 2010 Jun; 33(6):1282-7. PubMed ID: 20332355
[TBL] [Abstract][Full Text] [Related]
2. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.
Bakhtiani PA; El Youssef J; Duell AK; Branigan DL; Jacobs PG; Lasarev MR; Castle JR; Ward WK
J Diabetes Complications; 2015; 29(1):93-8. PubMed ID: 25264232
[TBL] [Abstract][Full Text] [Related]
4. Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System.
Castle JR; El Youssef J; Bakhtiani PA; Cai Y; Stobbe JM; Branigan D; Ramsey K; Jacobs P; Reddy R; Woods M; Ward WK
Diabetes Care; 2015 Nov; 38(11):2115-9. PubMed ID: 26341131
[TBL] [Abstract][Full Text] [Related]
5. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.
Ward WK; Castle JR; El Youssef J
J Diabetes Sci Technol; 2011 Nov; 5(6):1373-80. PubMed ID: 22226254
[TBL] [Abstract][Full Text] [Related]
6. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes.
Reiband HK; Schmidt S; Ranjan A; Holst JJ; Madsbad S; Nørgaard K
Diabetes Metab Res Rev; 2015 Oct; 31(7):672-9. PubMed ID: 25533565
[TBL] [Abstract][Full Text] [Related]
7. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
10. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
[TBL] [Abstract][Full Text] [Related]
11. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
[TBL] [Abstract][Full Text] [Related]
12. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
13. A bihormonal closed-loop artificial pancreas for type 1 diabetes.
El-Khatib FH; Russell SJ; Nathan DM; Sutherlin RG; Damiano ER
Sci Transl Med; 2010 Apr; 2(27):27ra27. PubMed ID: 20393188
[TBL] [Abstract][Full Text] [Related]
14. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
[TBL] [Abstract][Full Text] [Related]
15. Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.
Abitbol A; Rabasa-Lhoret R; Messier V; Legault L; Smaoui M; Cohen N; Haidar A
Diabetes Technol Ther; 2018 Mar; 20(3):189-196. PubMed ID: 29393675
[TBL] [Abstract][Full Text] [Related]
16. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
[TBL] [Abstract][Full Text] [Related]
17. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
Bally L; Thabit H; Hovorka R
Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
[No Abstract] [Full Text] [Related]
18. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
[TBL] [Abstract][Full Text] [Related]
19. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
[TBL] [Abstract][Full Text] [Related]
20. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.
El Youssef J; Castle JR; Bakhtiani PA; Haidar A; Branigan DL; Breen M; Ward WK
Diabetes Care; 2014 Nov; 37(11):3054-60. PubMed ID: 25139882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
